Why Corbion Is Walking Away from PLA: Follow the Money
Corbion has officially completed its exit from the TotalEnergies Corbion joint venture, ending its direct involvement in the production and marketing of Luminy® PLA resins. On the surface, a sustainability-focused company abandoning one of the most prominent bioplastics on the market seems counterintuitive. But when you look at Corbion’s financial trajectory and strategic calculus, the picture becomes remarkably clear: PLA manufacturing was dragging the company down, while its core food and health ingredients businesses were generating far superior returns.
The Numbers Don’t Lie
Corbion’s full-year 2025 results tell a compelling story. The company delivered organic adjusted EBITDA growth of 26.7%, earnings per share surged 63.3% to €1.29, and free cash flow hit €90.8 million — exceeding its own targets. So strong was the performance that Corbion announced a special dividend of €0.36 on top of its regular €0.64 payout, a clear signal of financial confidence.
But here’s the critical detail: this impressive performance was driven overwhelmingly by Corbion’s food ingredients and health & nutrition divisions — not by PLA.
The Functional Ingredients & Solutions unit, powered by natural food preservation, shelf-life extension, and specialty lactic acid derivatives, saw EBITDA margins improve by 230 basis points in 2025 through cost discipline and a shift toward higher-margin specialty products. Health & Nutrition, including the algae-based omega-3 business and biomedical polymers, delivered consistent volume growth with an EBITDA margin hovering around 30%.
Meanwhile, the PLA joint venture was a different story altogether. In 2024, the venture’s adjusted EBITDA margin sat at just 8.7% — far below Corbion’s group-wide margin of around 16%. The 2025 earnings call highlighted continued price erosion in the PLA market, further compressing margins. Put simply, PLA was the weakest link in Corbion’s portfolio.
A Long Goodbye: The Writing Was on the Wall
Corbion’s disengagement from PLA didn’t happen overnight. The timeline reveals a gradual, deliberate retreat:
2023: Corbion cancelled the planned Grandpuits PLA plant in France, citing capital discipline after reviewing the investment case. The joint venture booked a €6.8 million impairment on capitalized development costs for the project. This was the first concrete signal that Corbion was rethinking its downstream polymer ambitions.
November 2025: At its Capital Markets Day, Corbion unveiled its new “BRIGHT 2030” strategy, redefining itself explicitly as “a sustainable specialty food-ingredients company, focused on natural preservation and nutrition.” The presentation confirmed that a strategic ownership review of the PLA portfolio had been initiated. PLA was conspicuously absent from the company’s forward growth narrative.
February 2026: The exit was finalized. TotalEnergies assumed full operational control of the joint venture’s assets, including the 75,000-tonne PLA facility in Rayong, Thailand.
Why PLA Didn’t Fit Anymore
To understand Corbion’s decision, you need to appreciate the fundamental business model tension between being an upstream ingredients supplier and a downstream polymer manufacturer.
Corbion is, at its core, a fermentation company. Its competitive moat lies in its global leadership in lactic acid production — the technology, the scale, the geographic reach, and the breadth of its derivative portfolio. Lactic acid is a remarkably versatile molecule: it goes into food preservation, pharmaceutical excipients, biodegradable medical implants, cosmetics, cleaning agents, and, yes, PLA production.
The economics of these applications vary dramatically. Specialty lactic acid derivatives for food preservation or biomedical use command premium pricing and offer high margins with relatively low capital intensity. PLA production, on the other hand, requires massive polymerization assets, competes against commodity fossil-fuel plastics on price, and is subject to the brutal cyclicality of the polymer market.
By divesting the PLA joint venture, Corbion isn’t abandoning lactic acid for PLA — quite the opposite. Corbion will continue to supply lactic acid to TotalEnergies as a feedstock for PLA production. It captures the upstream value without bearing the capital burden and margin volatility of the downstream polymer business. This is classic “sell the shovels” strategy: let someone else mine the gold while you profit from the tools.
The Contrast in Margins Tells the Story
Consider the margin differential across Corbion’s businesses:
- Health & Nutrition (biomedical polymers, omega-3, pharma): ~30% EBITDA margin
- Functional Ingredients & Solutions (food preservation, lactic acid specialties): steadily improving, approaching 17-18%
- TotalEnergies Corbion PLA joint venture: ~8.7% EBITDA margin in 2024, under further pressure from price erosion
From a capital allocation perspective, every euro Corbion invested in supporting the PLA joint venture was a euro not invested in its higher-returning food and health businesses. The opportunity cost became untenable, especially as Corbion’s “BRIGHT 2030” strategy targets an overall group EBITDA margin of approximately 18% by 2028 and cumulative free cash flow of €270 million over the 2026-2028 period.
Keeping PLA in the portfolio would have been an anchor on those targets.
What This Means for the PLA Industry
For the broader bioplastics ecosystem, Corbion’s exit carries mixed implications.
On the positive side, TotalEnergies is a far larger entity with deeper pockets and a stronger appetite for capital-intensive commodity businesses. An energy major with integrated petrochemical operations may actually be better positioned to scale PLA production, manage raw material price volatility, and compete with fossil-fuel incumbents. TotalEnergies has signaled its commitment to growing the Luminy® brand as part of its own sustainability and biopolymer ambitions.
On the more sobering side, Corbion’s departure reinforces an uncomfortable truth about PLA economics: the margin profile of biopolymer manufacturing remains challenging. PLA competes in a market where the reference price is set by petroleum-derived plastics that benefit from decades of scale optimization and often implicit subsidies through unpriced externalities. Until carbon pricing, regulatory mandates, or further scale shifts fundamentally alter that equation, PLA will remain a tough business for pure-play chemical companies to justify on financial returns alone.
It also raises a broader strategic question for the bioplastics sector: does the future of PLA belong to specialty ingredient companies like Corbion, or to integrated energy and petrochemical conglomerates like TotalEnergies that can absorb the capital intensity and longer investment horizons? Corbion’s answer, emphatically, is the latter.
The Bigger Picture: Corbion’s Bet on Food
Corbion is placing its chips on what it does best — and where the money is. The company’s new strategy focuses on three interconnected megatrends: clean-label ingredients, natural food preservation, and sustainable nutrition.
The growth vectors here are genuinely compelling. Clean-label demand continues to accelerate as consumers and regulators push for transparency. Corbion’s fermentation-based preservation solutions directly displace synthetic additives, a trend with years of runway. In nutrition, the algae-based omega-3 platform addresses structural supply constraints in aquaculture and opens new opportunities in pet food and human nutrition.
These are higher-margin, lower-capital-intensity businesses with strong secular tailwinds — exactly the profile that generates sustainable shareholder value. Corbion’s 2025 results suggest the strategy is already delivering.
Conclusion: A Rational Decision, Not a Retreat from Sustainability
It’s tempting to frame Corbion’s PLA exit as a step backward for bioplastics. That would be a misreading of the situation. Corbion continues to produce the lactic acid that makes PLA possible. It remains deeply embedded in the bioplastics value chain — just at the part of the chain where it earns the best returns.
The real lesson here is about economic discipline in the sustainability space. Good intentions don’t generate shareholder returns; strong unit economics do. Corbion looked at its portfolio, saw where the value was being created, and made the rational decision to concentrate there. For the bioplastics industry, the message is clear: the route to mainstream adoption runs through economic competitiveness, not just environmental credentials.
TotalEnergies now carries the banner for Luminy® PLA. Whether it can crack the margin challenge that ultimately drove Corbion away will be one of the more interesting stories to watch in the bioplastics space over the coming years.
This article reflects the author’s analysis based on publicly available financial data and company announcements. It does not constitute investment advice.